Small Animal Radiation Research Platform with Cone-beam CT Guidance

锥束CT引导小动物放射研究平台

• 批准号: 7795538
• 负责人: James M Larner
• 金额: $ 49.89万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-10 至 2010-12-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7795538
• 关键词: Adoption; Animals; Area; Arts; Cardiovascular Diseases; Clinical Treatment; Collimator; Coupling; DNA Damage; Dose; Ensure; Environment; Gynecologic; Image; Immunology; Immunotherapy; In Vitro; Investigation; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Molecular Target; Patients; Pharmaceutical Preparations; Radiation; Radiation Interaction; Radiation Oncology; Radiation Physics; Radiation therapy; Research; Resistance; Roentgen Rays; Solid Neoplasm; System; Testing; Universities; University of Virginia Cancer Center; Virginia; base; cell killing; chemotherapy; cone-beam computed tomography; design; improved; irradiation; medical schools; neoplastic cell; neuro-oncology; preclinical study; response; small molecule; three-dimensional modeling; tool

DESCRIPTION (provided by applicant): The University of Virginia School of Medicine currently has an obsolete 40-year-old orthovoltage XRAY machine which is used for irradiation of small animals. This proposal is to replace our obsolete irradiator with a state of the art small animal radiation research platform (SARRP) irradiator. In addition to delivering radiation in vitro, SARRP is the first system that integrates collimation, accurate dose modeling and 3D volumetric imaging guidance into a single platform thereby allowing highly conformal dose distributions to be achieved in animals. The SARRP provides an important tool in moving us to the era where small molecules, radiation, and immunotherapy are used synergistically. Radiation is the most active agent against most solid tumors. Recent improvements in radiation physics have led to dramatic improvements in radiation delivery, allowing elegant spatial targeting of the radiation dose. However, escalating spatially targeted doses has had only minimal impact on the local control rates of most solid tumors. One key advantage of radiation is that in contrast to essentially all chemotherapeutic and all molecular target agents, radiation does not induce resistance. Therefore, coupling spatially targeted radiation therapy with molecularly targeted agents designed to enhance tumor cell kill holds tremendous potential to improve local control rates of solid tumors. Indeed most patients treated in Radiation Oncology Departments for cure are treated with a combination of radiation and chemotherapy or molecularly targeted therapy. Identifying the optimal agents to use in combination with radiation as well as defining the mechanistic basis of drug/radiation interactions requires preclinical studies using focused radiation in order to mimic actual clinical treatments. The availability of an irradiator with these capabilities will stimulate such studies testing specific agents currently under investigation at the University of Virginia Cancer Center in the specific areas of neuro-oncology and prostate cancer as well as in the broad area of DNA damage response. As the first tier of investigations prove successful, we anticipate use in gynecologic, lung, and GI cancers and more generally. In addition to oncologic investigations, the SARRP will also facilitate research in the areas of immunology and cardiovascular diseases. The collaborative and communicative environment at UVA will ensure the rapid adoption of SARRP approach in a wide array of indications.

描述（由申请人提供）：弗吉尼亚大学医学院目前有一台已过时的40年历史的Orthovaltage X射线机，用于辐射小动物。该建议是用最先进的小动物辐射研究平台（SARRP）辐射器代替过时的辐照体。除了在体外传递辐射外，SARRP还是第一个集成了准确的剂量建模，准确的剂量建模和3D体积成像指南的系统，从而允许在动物中实现高度保形剂量分布。 SARRP提供了一种重要的工具，可以将我们转移到协同使用小分子，放射线和免疫疗法的时代。辐射是针对大多数实体瘤的最活跃剂。辐射物理学的最新改善导致了辐射递送的巨大改善，从而使辐射剂量的空间靶向优雅。然而，空间靶向剂量的升级仅对大多数实体瘤的局部控制速率产生最小的影响。辐射的一个关键优点是，与所有化学治疗和所有分子靶标相反，辐射不会诱导耐药性。因此，旨在增强肿瘤细胞杀死的分子靶向药物的空间靶向放射疗法具有提高实体瘤的局部控制速率的巨大潜力。实际上，在放射肿瘤学部门治疗的大多数患者都通过放射和化学疗法或分子靶向治疗的结合进行治疗。确定与辐射结合使用的最佳药物以及定义药物/辐射相互作用的机理基础，需要使用聚焦辐射来模仿实际的临床治疗。具有这些能力的辐照体的可用性将刺激此类研究，该研究对目前在弗吉尼亚大学癌症中心正在研究的特定特定领域的神经肿瘤和前列腺癌以及DNA损伤反应的广泛领域进行了研究。作为第一层的研究证明是成功的，我们预计将在妇科，肺和GI癌症等中使用。除了肿瘤学调查外，SARRP还将促进免疫学和心血管疾病领域的研究。 UVA的协作和沟通环境将确保在各种适应症中快速采用SARRP方法。